Fixation on HbA1C is ‘fundamentally flawed’

It’s a “fundamentally flawed” strategy to fixate exclusively on HbA1C, according to US and UK reseachers who say endocrinologists should consider patient preferences, quality of life and the “burden” of treatment.

The researchers, led by Dr Sandeep Vijan of the University of Michigan, draw on seminal studies such as the UKPDS and DCCT trials to establish the clinical benefits of lowering HbA1C from 8.5% to 7.5%. Their study then plots these against the number of quality-adjusted life